Autopsy report · NCT01053884
Anidulafungin in Patients With Hematologic Malignancies
Cause of deathSlow enrollment
“reduced recruitment rate due to non infectious, but competitive trials at our institution”
Life of this trial
- Registered 3 months after it had already started.
- Ran for about 1 year 11 months before it stopped.
- 10 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Elisabethinen Hospital
- Sponsor type
- University, hospital or other
- Conditions
- Hematologic Malignancies
- Interventions
- Anidulafungin
- Participants
- 10
- Sites
- 1
- Countries
- Austria
Trials that died the same way
- Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly
“Recruitment rate dropped because of national COVID-19 vaccination campaign taking place parallel to this study.” - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
“Low recruitment rate due to treatment regimen change” - Comparing Satisfaction With a Participatory Driven Web-application and a Standard Website
“The primary trial was stopped. Since, a feasibility study showed that recruitment was not feasible. We obtain a recruitment rate of 15 %.” - Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
“Due to the low recruitment rate since the start of the trial” - The Effect of Episiotomy on Maternal and Fetal Outcomes (EPITRIAL)
“Slower than expected recruitment rate, and larger than expected required sample.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.